208 related articles for article (PubMed ID: 4198657)
1. Immunity to brucella infection.
Elberg SS
Medicine (Baltimore); 1973 Jul; 52(4):339-56. PubMed ID: 4198657
[No Abstract] [Full Text] [Related]
2. Immunological methods in brucellosis research. II. In vivo procedures.
Olitzki A
Bibl Microbiol; 1970; 9():1-299. PubMed ID: 4913957
[No Abstract] [Full Text] [Related]
3. [Immunobiological properties of the protective brucellosis antigen].
Dranovskaia EA; Vershilova PA; Grekova NA
Zh Mikrobiol Epidemiol Immunobiol; 1974 Sep; (9):66-70. PubMed ID: 4216217
[No Abstract] [Full Text] [Related]
4. [On the question of the characteristics of brucellae isolated on the territory of the USSR. II. Comparative virulence of different biotypes of the Brucella species melitensis, abortus and suis].
Kaĭtmazova EI; Ostrovskaia NN
Zh Mikrobiol Epidemiol Immunobiol; 1967 Feb; 44(2):66-70. PubMed ID: 4973047
[No Abstract] [Full Text] [Related]
5. Brucella abortus 2308ΔNodVΔNodW double-mutant is highly attenuated and confers protection against wild-type challenge in BALB/c mice.
Li Z; Wang S; Zhang J; Yang G; Yuan B; Huang J; Han J; Xi L; Xiao Y; Chen C; Zhang H
Microb Pathog; 2017 May; 106():30-39. PubMed ID: 28131952
[TBL] [Abstract][Full Text] [Related]
6. Orally administrable brucellosis vaccine: Brucella suis strain 2 vaccine.
Xin X
Vaccine; 1986 Dec; 4(4):212-6. PubMed ID: 3541425
[TBL] [Abstract][Full Text] [Related]
7. Improved influenza viral vector based Brucella abortus vaccine induces robust B and T-cell responses and protection against Brucella melitensis infection in pregnant sheep and goats.
Mailybayeva A; Yespembetov B; Ryskeldinova S; Zinina N; Sansyzbay A; Renukaradhya GJ; Petrovsky N; Tabynov K
PLoS One; 2017; 12(10):e0186484. PubMed ID: 29023541
[TBL] [Abstract][Full Text] [Related]
8. Completing the eradication of brucellosis by 1975.
Schilf EA
J Am Vet Med Assoc; 1972 Dec; 161(11):1525-7. PubMed ID: 4629394
[No Abstract] [Full Text] [Related]
9. Rough vaccines in animal brucellosis: structural and genetic basis and present status.
Moriyón I; Grilló MJ; Monreal D; González D; Marín C; López-Goñi I; Mainar-Jaime RC; Moreno E; Blasco JM
Vet Res; 2004; 35(1):1-38. PubMed ID: 15099501
[TBL] [Abstract][Full Text] [Related]
10. Enzyme-linked immunosorbent assay to differentiate the antibody responses of animals infected with Brucella species from those of animals infected with Yersinia enterocolitica O9.
Erdenebaatar J; Bayarsaikhan B; Watarai M; Makino S; Shirahata T
Clin Diagn Lab Immunol; 2003 Jul; 10(4):710-4. PubMed ID: 12853409
[TBL] [Abstract][Full Text] [Related]
11. [Immunity status of guinea pigs infected with Brucella L forms].
Vershilova PA; Tolmacheva TA
Zh Mikrobiol Epidemiol Immunobiol; 1982 Sep; (9):107-9. PubMed ID: 6815938
[TBL] [Abstract][Full Text] [Related]
12. [Phenol-insoluble vaccine against human brucellosis: evaluation of the immunogenic power in guinea pigs].
Bolpe J; de Lapenta DF; García-Carrillo C
Rev Inst Med Trop Sao Paulo; 1991; 33(1):23-7. PubMed ID: 1843392
[TBL] [Abstract][Full Text] [Related]
13. Brucellosis vaccines based on the open reading frames from genomic island 3 of Brucella abortus.
Gómez L; Alvarez F; Betancur D; Oñate A
Vaccine; 2018 May; 36(21):2928-2936. PubMed ID: 29685597
[TBL] [Abstract][Full Text] [Related]
14. Prime-booster vaccination of cattle with an influenza viral vector Brucella abortus vaccine induces a long-term protective immune response against Brucella abortus infection.
Tabynov K; Yespembetov B; Ryskeldinova S; Zinina N; Kydyrbayev Z; Kozhamkulov Y; Inkarbekov D; Sansyzbay A
Vaccine; 2016 Jan; 34(4):438-444. PubMed ID: 26709638
[TBL] [Abstract][Full Text] [Related]
15. Intermediate rough Brucella abortus S19Δper mutant is DIVA enable, safe to pregnant guinea pigs and confers protection to mice.
Lalsiamthara J; Gogia N; Goswami TK; Singh RK; Chaudhuri P
Vaccine; 2015 May; 33(22):2577-83. PubMed ID: 25869887
[TBL] [Abstract][Full Text] [Related]
16. [Persistence of brucellosis L cultures in the body of an experimental animal and the duration of immunity].
Vershilova PA; Grekova NA; Tolmacheva TA
Vestn Akad Med Nauk SSSR; 1985; (3):10-3. PubMed ID: 3922151
[No Abstract] [Full Text] [Related]
17. [On the question of the necessity of changing place of work in brucella infection and following residual brucellosis].
Töppich E; Krüger W
Z Gesamte Inn Med; 1966 Jun; 21(12):372-4. PubMed ID: 6011096
[No Abstract] [Full Text] [Related]
18. A recent trial comparing two 45/20 adjuvant Brucella vaccines.
McKeon FW
Dev Biol Stand; 1976; 31():343-50. PubMed ID: 816690
[TBL] [Abstract][Full Text] [Related]
19. Brucella melitensis Rev. 1 and Brucella abortus 45-20 vaccines in goats: serologic tests.
Jones LM; García-Carrillo C; Alton GG
Am J Vet Res; 1973 Feb; 34(2):199-202. PubMed ID: 4631096
[No Abstract] [Full Text] [Related]
20. Selection of a Brucella vaccine strain of low residual virulence by chemical mutagenesis.
Zhao WR; Wendoso ; Hasi ; Qin YX; Weng W; Lu SL
J Med Microbiol; 1989 Oct; 30(2):143-8. PubMed ID: 2795638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
